Cargando…
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
The site of action of aminoglutethimide (AG) has been investigated. An initial study was performed on 10 postmenopausal patients with advanced breast cancer who had taken 1000 mg AG per day and 20 mg hydrocortisone (HC) twice daily (b.d.) for greater than 3 months. There was a 15.5 +/- 5.6 s.e.-fold...
Autores principales: | Harris, A. L., Dowsett, M., Smith, I. E., Jeffcoate, S. L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1983
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011397/ https://www.ncbi.nlm.nih.gov/pubmed/6221746 |
Ejemplares similares
-
Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984) -
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1985) -
Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1983) -
Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1985) -
The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.
por: Dowsett, M., et al.
Publicado: (1988)